Provided by Tiger Trade Technology Pte. Ltd.

Apogee Therapeutics

69.81
-0.1900-0.27%
Volume:86.01K
Turnover:5.86M
Market Cap:4.77B
PE:-16.01
High:70.66
Open:67.36
Low:67.11
Close:70.00
52wk High:84.56
52wk Low:26.20
Shares:68.32M
Float Shares:47.47M
Volume Ratio:1.66
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3614
EPS(LYR):-3.3001
ROE:-38.41%
ROA:-25.26%
PB:8.13
PE(LYR):-21.15

Loading ...

Apogee Therapeutics Cut to Sector Perform From Outperform by RBC Capital

Dow Jones
·
Jan 22

RBC Downgrades Apogee Therapeutics to Sector Perform From Outperform, Raises Price Target to $83 From $70, Keeps Speculative Risk

MT Newswires Live
·
Jan 22

Apogee Therapeutics downgraded to Sector Perform from Outperform at RBC Capital

TIPRANKS
·
Jan 22

Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE) and GoodRx Holdings (GDRX)

TIPRANKS
·
Jan 19

Apogee Therapeutics CEO Michael Thomas Henderson Reports Disposal of Common Shares

Reuters
·
Jan 17

Funding for Risky Biotechs Is Returning -- WSJ

Dow Jones
·
Jan 13

Apogee Therapeutics Chief Medical Officer Carl Dambkowski Reports Disposal of Common Shares

Reuters
·
Jan 10

Apogee Therapeutics Initiated at Peer Perform by Wolfe Research

Dow Jones
·
Jan 08

UBS Initiates Apogee Therapeutics at Buy With $100 Price Target

MT Newswires Live
·
Jan 07

BUZZ-U.S. STOCKS ON THE MOVE-United Airlines Holdings, Energy companies, Tesla

Reuters
·
Jan 07

Apogee Therapeutics Inc : Btig Raises Target Price to $137 From $128

THOMSON REUTERS
·
Jan 07

BUZZ-U.S. STOCKS ON THE MOVE-Shake Shack, Arrowhead Pharmaceuticals, Lockheed Martin

Reuters
·
Jan 06

BUZZ-U.S. STOCKS ON THE MOVE-Alkermes, Ball Corp, NovaBridge

Reuters
·
Jan 06

Apogee Therapeutics Shares Add 1.7% Premarket After Asthma Drug Shows Promise in Early Trial

THOMSON REUTERS
·
Jan 06

BUZZ-Apogee Therapeutics rises as asthma drug shows promise in early trial

Reuters
·
Jan 06

Apogee Therapeutics Announces Positive Interim Results From Phase 1B Trial of Zumilokibart (Apg777), Its Potentially Best-in-Class Anti-Il-13 Antibody, in Patients With Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

THOMSON REUTERS
·
Jan 06

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

GlobeNewswire
·
Jan 06

U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR Infrastructure

Reuters
·
Jan 06

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026

GlobeNewswire
·
Jan 06

Apogee Therapeutics Is Maintained at Buy by BTIG

Dow Jones
·
Jan 05